Literature DB >> 17162603

Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome.

Mamta Agarwal1, Sudha K Ganesh, Jyotirmay Biswas.   

Abstract

PURPOSE: To describe the role of triple agent immunosuppression in severe recalcitrant cases of Vogt-Koyanagi-Harada syndrome.
MATERIALS AND METHODS: Retrospective chart review of five cases of Vogt-Koyanagi-Harada syndrome.
RESULTS: All cases were treated with oral prednisolone, azathioprine, and cyclosporine in combination, and rapid remission was observed in all patients. The synergistic effect of the triple agent immunosuppressives helped in preventing recurrences. Prolonged treatment with steroid sparing immunosuppressives in severe and recalcitrant cases of Vogt-Koyanagi-Harada syndrome maintained disease remission.
CONCLUSION: Severe cases of Vogt-Koyanagi-Harada syndrome can be treated with early use of high-dose triple agent immunosuppressives.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17162603     DOI: 10.1080/09273940600976938

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  8 in total

1.  Clinicopathological and immunohistochemistry correlation in a case of Vogt-Koyanagi-Harada disease.

Authors:  Dipankar Das; Anusha Boddepalli; Jyotirmay Biswas
Journal:  Indian J Ophthalmol       Date:  2019-07       Impact factor: 1.848

2.  [Vogt-Koyanagi-Harada Syndrome : An unusual case with lacquer crack-like retinal findings].

Authors:  M Parlak; G Kocaoglu; A O Saatci
Journal:  Ophthalmologe       Date:  2017-12       Impact factor: 1.059

3.  Postsurgical sympathetic ophthalmia: retrospective analysis of a rare entity.

Authors:  Parthopratim Dutta Majumder; Eliza Anthony; Amala Elizabeth George; Sudha K Ganesh; Jyotirmay Biswas
Journal:  Int Ophthalmol       Date:  2017-11-21       Impact factor: 2.031

4.  Cell Death Pathways in Mutant Rhodopsin Rat Models Identifies Genotype-Specific Targets Controlling Retinal Degeneration.

Authors:  Ishaq A Viringipurampeer; Cheryl Y Gregory-Evans; Andrew L Metcalfe; Emran Bashar; Orson L Moritz; Kevin Gregory-Evans
Journal:  Mol Neurobiol       Date:  2018-06-18       Impact factor: 5.590

5.  [Autofluorescence combined with spectral domain optical coherence tomography for diagnosis and follow-up of acute Vogt-Koyanagi-Harada disease].

Authors:  Shuwei Tian; Jing Yao; Jianming Wang; Jie Zhang; Aiyi Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-01-30

Review 6.  Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.

Authors:  Ioannis Papasavvas; Ilknur Tugal-Tutkun; Carl P Herbort
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-24

7.  Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study.

Authors:  Ana Belen Rivas; Amanda Lopez-Picado; Valentina Calamia; Ester Carreño; Lidia Cocho; Miguel Cordero-Coma; Alex Fonollosa; Felix M Francisco Hernandez; Angel Garcia-Aparicio; Javier Garcia-Gonzalez; Jose Juan Mondejar; Leticia Lojo-Oliveira; Llucí Martínez-Costa; Santiago Munoz; Diana Peiteado; Jose Antonio Pinto; Beatriz Rodriguez-Lozano; Esperanza Pato; David Diaz-Valle; Elena Molina; Luis Alberto Tebar; Luis Rodriguez-Rodriguez
Journal:  BMJ Open       Date:  2022-03-22       Impact factor: 2.692

Review 8.  miRNA Landscape in Pathogenesis and Treatment of Vogt-Koyanagi-Harada Disease.

Authors:  Fabian Vega-Tapia; Mario Bustamante; Rodrigo A Valenzuela; Cristhian A Urzua; Loreto Cuitino
Journal:  Front Cell Dev Biol       Date:  2021-05-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.